Treatment discontinuation rates due to lack of efficacy through 1 year of maintenance treatment with vedolizumab or subcutaneous infliximab in patients with inflammatory bowel disease: a systematic literature review and meta-analysis.

Saved in:
Bibliographic Details
Title: Treatment discontinuation rates due to lack of efficacy through 1 year of maintenance treatment with vedolizumab or subcutaneous infliximab in patients with inflammatory bowel disease: a systematic literature review and meta-analysis.
Authors: Ferrante, Marc1,2, Peyrin-Biroulet, Laurent3,4,5, Arkkila, Perttu6,7, Armuzzi, Alessandro8,9, Colombel, Jean-Frédéric10, Danese, Silvio11, Faggiani, Roberto12, Guardiola, Jordi13, Hanauer, Stephen B.14, Jahnsen, Jorgen15, Reinisch, Walter16, Roblin, Xavier17, Smith, Philip J.18, Taek Sang Kwon19, Seungmin Kim19, Kyoungwan Nam19, Atreya, Raja20 raja.atreya@uk-erlangen.de
Source: Therapeutic Advances in Gastroenterology. 10/8/2025, Vol. 18, p1-12. 12p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:1756283X
DOI:10.1177/17562848251383767